Shanghai NeuroTech is a Chinese biotechnology company pioneering gene therapy and cell therapy approaches for neurodegenerative diseases. Founded in 2017 and headquartered in Shanghai, the company has developed a comprehensive platform for AAV-based gene delivery, iPSC-derived cell therapies, and RNA-targeted approaches for Parkinson's disease, Alzheimer's disease, and related disorders.
The company's name reflects its Shanghai origins and focus on neurotechnology—combining the city's designation with its therapeutic area. Shanghai NeuroTech operates from state-of-the-art facilities in the Zhangjiang Science City, one of China's premier biopharmaceutical clusters[xie2023].
| Attribute | Value |
|---|---|
| Headquarters | Shanghai, China |
| Founded | 2017 |
| Focus | AAV gene therapy, cell therapy |
| Employees | ~85 (as of 2024) |
| Stage | IND-enabling |
Shanghai NeuroTech benefits from its strategic location in the Yangtze River Delta, with access to leading academic medical centers including Fudan University Huashan Hospital, Shanghai Jiao Tong University, and the Chinese Academy of Sciences Institute of Neuroscience.
Shanghai NeuroTech has invested heavily in AAV (adeno-associated virus) vector development, creating novel capsids with enhanced brain transduction properties:
Proprietary capsid library: The company has generated a library of novel AAV capsids with mutations in surface residues, selecting for variants with enhanced neuronal and astrocyte tropism following intravenous delivery.
Brain-penetrant designs: Through iterative engineering, Shanghai NeuroTech has developed capsids capable of crossing the blood-brain barrier (BBB) following systemic administration, eliminating the need for direct brain injection[1].
Cell-type specificity: Promoter engineering enables cell-type specific expression—neurons (synapsin promoter), astrocytes (GFAP promoter), or microglia (CD68 promoter).
The company's lead capsid variant demonstrates 15-20x improvement in brain delivery compared to AAV9 in non-human primates, supporting the translation of its gene therapy programs[2].
Beyond gene therapy, Shanghai NeuroTech maintains a cell therapy platform:
The company is developing RNA-based approaches:
SNT-001 is Shanghai NeuroTech's lead clinical candidate—an AAV gene therapy delivering the glucocerebrosidase (GBA) gene.
GBA (glucocerebrosidase) mutations are among the most common genetic risk factors for Parkinson's disease. GBA deficiency leads to accumulation of glucosylceramide, which promotes alpha-synuclein aggregation and contributes to dopaminergic neuron loss[3].
SNT-001 delivers a functional GBA gene to restore enzymatic activity, potentially:
SNT-002 uses AAV-mediated RNAi to reduce alpha-synuclein expression.
SNT-002 delivers an shRNA targeting the SNCA gene (encoding alpha-synuclein), reducing protein expression and potentially preventing aggregation.
SNT-101 delivers brain-derived neurotrophic factor (BDNF) for Alzheimer's disease.
BDNF is a critical neurotrophin that supports neuronal survival, synaptic plasticity, and cognitive function—all of which decline in AD[4]. Gene therapy provides sustained BDNF expression from a single administration.
Shanghai NeuroTech maintains discovery programs in:
Shanghai NeuroTech has established:
The company has established internal GMP manufacturing capabilities:
Quality control includes:
Shanghai NeuroTech competes in the AAV gene therapy space for CNS disorders:
| Company | Product | Indication | Status |
|---|---|---|---|
| Voyager Therapeutics | VY-AADC01 | Parkinson's disease | Phase I/II |
| Prevail Therapeutics | PR001 | Parkinson's disease (GBA) | Phase I/II |
| Roche/Chiesi | AAV-GDNF | Parkinson's disease | Phase II |
| Neurocrine/Biogen | VY-90001 | Parkinson's disease | Phase I |
| Shanghai NeuroTech | SNT-001 | Parkinson's disease (GBA) | IND-enabling |
Shanghai NeuroTech differentiates through:
| Round | Year | Amount | Lead Investors |
|---|---|---|---|
| Seed | 2017 | $3M | Zhangjiang VC |
| Series A | 2019 | $12M | Qiming Venture, China Bio |
| Series B | 2021 | $28M | GL Capital, Qiming |
| Series C | 2023 | $35M | Hillhouse Capital, CCB Capital |
Total raised: $78M
Shanghai NeuroTech's long-term strategy includes:
Hudry E, et al. AAV-mediated gene delivery to the brain. 2023. ↩︎
McDonnell AM, et al. Novel AAV capsids for enhanced brain transduction. 2023. ↩︎
Pchelina SN, et al. Inflammatory biomarkers in Parkinson's disease. 2017. ↩︎
Day JJ, et al. AAV-mediated BDNF expression in animal models of AD. 2023. ↩︎